NCT01324583 - Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Prostate Cancer

Interventions

DRUG

Cabazitaxel (XRP6258)

"Pharmaceutical form:solution~Route of administration: intravenous"

DRUG

prednisolone

"Pharmaceutical form:tablet~Route of administration: oral"

Trial Locations (21)

Investigational Site Number 392011, Bunkyō City

Investigational Site Number 392021, Fukuoka

Investigational Site Number 392014, Hamamatsu

Investigational Site Number 392009, Itabashi-Ku

Investigational Site Number 392001, Kashiwa-Shi

Investigational Site Number 392020, Kita-Gun

Investigational Site Number 392002, Kōtoku

Investigational Site Number 392016, Kyoto

Investigational Site Number 392017, Kyoto

Investigational Site Number 392008, Maebashi

Investigational Site Number 392012, Minatoku

Investigational Site Number 392015, Nagoya

Investigational Site Number 392019, Osaka Sayama-Shi

Investigational Site Number 392004, Sapporo

Investigational Site Number 392005, Sendai

Investigational Site Number 392010, Shinjuku-Ku

Investigational Site Number 392018, Suita-Shi

Investigational Site Number 392003, Sunto-Gun

Investigational Site Number 392007, Tsukuba

Investigational Site Number 392006, Yamagata

Investigational Site Number 392013, Yokohama